Varicella Vaccine Administration Guidelines

Primary Vaccination Schedule

The American Academy of Pediatrics recommends that all healthy children receive their first dose of varicella-containing vaccine routinely at 12-15 months of age 1, 2, 3, 4
The vaccine is approved for use starting at 12 months of age, according to the Centers for Disease Control and Prevention 1
The second dose is routinely recommended at 4-6 years of age (before entering prekindergarten, kindergarten, or first grade) 1, 2, 3, 4
The second dose may be administered at an earlier age, provided the minimum interval between doses is met, as stated by the Centers for Disease Control and Prevention 2, 3
This timing is strategically chosen because varicella incidence and outbreaks are higher among elementary school-aged children compared to preschool-aged children, according to the Centers for Disease Control and Prevention 2, 4

Minimum Intervals Between Doses

The minimum interval between first and second doses is 3 months for children 12 months through 12 years, as recommended by the American Academy of Pediatrics 1, 2, 3, 4
For persons 13 years and older, the minimum interval between doses is 4 weeks (28 days) 1, 2, 3, 4
Adolescents and adults without evidence of immunity should receive two 0.5-mL doses separated by at least 28 days, according to the Centers for Disease Control and Prevention 1, 2, 3

School Entry Requirements

All children entering school should have received two doses of varicella-containing vaccine or have other evidence of immunity, as required by the Centers for Disease Control and Prevention 2, 3, 4
The high transmission risk in school settings necessitates this requirement, according to the Centers for Disease Control and Prevention 2, 3

Available Vaccine Formulations

Monovalent varicella vaccine (Varivax) is approved for ages ≥12 months, as stated by the American Academy of Pediatrics 1
Combination MMRV vaccine (ProQuad) is approved only for ages 12 months through 12 years, according to the Centers for Disease Control and Prevention 1, 2, 3
Only single-antigen varicella vaccine may be used for persons ≥13 years, as recommended by the Centers for Disease Control and Prevention 2, 3

Special Populations Requiring Priority Vaccination

Adults at increased risk who lack evidence of immunity should receive special consideration for two-dose vaccination, including healthcare personnel, household contacts of immunocompromised persons, teachers and daycare employees, college students and military personnel, nonpregnant women of childbearing age, and international travelers, as stated by the Centers for Disease Control and Prevention 3

Varicella Vaccine Administration Guidelines

Recommended Timing for Varicella Vaccine Doses

For children 12 months through 12 years of age, the American Academy of Pediatrics recommends a minimum interval of 3 months between two doses of varicella vaccine 5
If the second dose is inadvertently administered between 28 days and 3 months after the first dose, the second dose does not need to be repeated, as per the Centers for Disease Control and Prevention guidelines 5, 6
For persons aged 13 years and older, the minimum interval between doses is 4 weeks (28 days), according to the Centers for Disease Control and Prevention recommendations 5, 7

Rationale for Timing Requirements

The 3-month minimum interval recommendation for children is based on the design of studies evaluating 2 doses of varicella vaccine in children aged 12 months to 12 years, as reported by the Centers for Disease Control and Prevention 7
Two doses of varicella vaccine provide significantly better protection than a single dose, with a vaccine efficacy of 98% compared to 94% for a single dose, as stated by the American Academy of Pediatrics 6, 8
Recipients of 2 doses are 3.3-fold less likely to have breakthrough varicella compared to those who received only 1 dose, according to the American Academy of Pediatrics 8, 9

Clinical Benefits of Two-Dose Varicella Vaccination

A two-dose varicella immunization schedule is recommended to achieve greater levels of immunity with fewer susceptible individuals, as recommended by the American Academy of Pediatrics 10, 11
Two doses provide greater protection against breakthrough varicella disease and reduce the number of outbreaks among school-aged populations, according to the American Academy of Pediatrics 12
After two doses, >99% of children achieve protective antibody levels against varicella, compared to 76-85% after a single dose, as reported by the Centers for Disease Control and Prevention 7

Varicella Vaccination Guidelines for Children

Recommended Vaccination Schedule

The American Academy of Pediatrics recommends that a 7-year-old child who has never received varicella vaccine should receive two doses of varicella vaccine administered at least 3 months apart, with the second dose acceptable if given as early as 28 days after the first dose 13, 14, 15
For children aged 7 years who have never been vaccinated, the first dose should be administered immediately at the current visit, and the second dose should be scheduled 3 months later as the recommended interval 13, 14, 15
The minimum acceptable interval between doses is 28 days, though this is not the preferred timing 13, 14

Critical Implementation Points

There is no need to restart the vaccine series regardless of time elapsed, and this child simply needs to begin the two-dose series now 13, 14

Varicella Vaccine Administration Guidelines

Contraindications and Precautions

The American Academy of Pediatrics recommends that individuals with a history of severe anaphylactic reaction to vaccine components, such as neomycin or gelatin, should not receive the varicella vaccine 16
Pregnancy is a contraindication for varicella vaccine administration, as recommended by the American Academy of Pediatrics 17
Individuals with known altered immunity, such as those with HIV and CD4 <15%, hematologic or solid tumors, congenital immunodeficiency, or those on long-term immunosuppressive therapy, should not receive the varicella vaccine 16
The American Academy of Pediatrics recommends that high-dose systemic corticosteroids (≥2 mg/kg/day prednisone or ≥20 mg/day) for ≥14 days is a contraindication for varicella vaccine administration 18, 17, 16, 19
The Centers for Disease Control and Prevention recommends waiting at least 1 month after discontinuing corticosteroid therapy before vaccinating 18, 17, 16, 19

Special Populations

HIV-infected children may receive the varicella vaccine if they have a CD4 T-lymphocyte percentage ≥15%, using 2 doses of monovalent vaccine with a 3-month interval, as recommended by the American Academy of Pediatrics 18, 17, 16, 19
Leukemic children in remission should not be routinely immunized with the varicella vaccine, but vaccination may be considered with expert guidance and availability of antiviral therapy, as recommended by the American Academy of Pediatrics 18, 17, 19

Postexposure Prophylaxis

The Centers for Disease Control and Prevention recommends that unvaccinated persons exposed to varicella should receive the vaccine within 3 days of exposure (up to 5 days may provide some benefit) 20
Vaccination within 3 days is >90% effective in preventing varicella, and vaccination within 5 days is approximately 70% effective in preventing varicella and 100% effective in modifying severe disease, as reported by the Centers for Disease Control and Prevention 20
The Centers for Disease Control and Prevention recommends avoiding salicylates for 6 weeks after vaccination due to the risk of Reye syndrome 20
Egg allergy is not a contraindication for varicella vaccine administration, as the vaccine contains no egg protein, according to the American Academy of Pediatrics 18, 17, 16, 19

Varicella Vaccination Recommendations

Primary Vaccination Schedule

The Centers for Disease Control and Prevention recommends administering the second dose of varicella vaccine at 4-6 years of age, with a minimum interval of 3 months between doses, for all healthy children 21
The second dose may be given earlier, provided the minimum 3-month interval is maintained, as recommended by the Centers for Disease Control and Prevention 21

Minimum Intervals Between Doses

The Centers for Disease Control and Prevention recommends a minimum interval of 3 months between the first and second doses of varicella vaccine for children 12 months to 12 years 21, 22
For adolescents and adults ≥13 years, the minimum interval is 4 weeks (28 days) between doses, as recommended by the Centers for Disease Control and Prevention 21, 22

Catch-Up Vaccination

The Centers for Disease Control and Prevention recommends that all children and adolescents who received only 1 dose of varicella vaccine previously should receive a second dose 21, 23

Available Vaccine Formulations

The Centers for Disease Control and Prevention recommends using single-antigen varicella vaccine for persons ≥13 years, as MMRV vaccine is not licensed for this age group 21, 22
The combination MMRV vaccine is approved only for children aged 12 months through 12 years, as recommended by the Centers for Disease Control and Prevention 21, 22

Rationale for Two-Dose Schedule

Recipients of 2 doses of varicella vaccine are 3.3-fold less likely to experience breakthrough varicella, according to the Centers for Disease Control and Prevention 23
After two doses, >99% of children achieve protective antibody levels, compared to 76-85% after a single dose, as reported by the Centers for Disease Control and Prevention 23

School Entry Requirements

The Centers for Disease Control and Prevention recommends that all children entering school should have received two doses of varicella vaccine or have other evidence of immunity 21, 22

Special Populations

The Centers for Disease Control and Prevention recommends that healthcare workers must be vaccinated against varicella due to the risk of VZV transmission in healthcare settings 21

Varicella Vaccine Administration Guidelines

Introduction to Varicella Vaccination

The Centers for Disease Control and Prevention recommends that the varicella vaccine is administered as a 0.5 mL dose given subcutaneously, using either single-antigen Varivax for all ages ≥12 months or combination ProQuad (MMRV) for children aged 12 months through 12 years only 24.

Dose and Route of Administration

Each dose is 0.5 mL administered subcutaneously, as recommended by the Centers for Disease Control and Prevention 24, 25.

Available Vaccine Products and Their Characteristics

The single-antigen Varivax vaccine is approved for all individuals ≥12 months of age, including adolescents and adults, as stated by the American Academy of Pediatrics 24, 26.
The combination MMRV vaccine (ProQuad) is approved only for children aged 12 months through 12 years, according to the Centers for Disease Control and Prevention 24, 25, 26.
The single-antigen Varivax vaccine contains a minimum of 1,350 plaque-forming units (PFUs) of Oka/Merck varicella-zoster virus per 0.5 mL dose, as specified by the Centers for Disease Control and Prevention 27.

Vaccination Schedule

For children 12 months through 12 years, the first dose of varicella vaccine should be administered at 12-15 months of age, and the second dose at 4-6 years of age, as recommended by the American Academy of Pediatrics 24, 25.
For adolescents and adults ≥13 years, two 0.5 mL doses of single-antigen Varivax vaccine should be administered, separated by a minimum of 4 weeks (28 days), according to the Centers for Disease Control and Prevention 24, 25.

Clinical Efficacy of the Two-Dose Regimen

The two-dose regimen of varicella vaccine provides 98% efficacy against any varicella disease and 100% efficacy against severe disease, compared to 94% efficacy with one dose, as reported by the American Academy of Pediatrics 26.
Recipients of two doses are 3.3-fold less likely to experience breakthrough varicella compared to one-dose recipients, according to the American Academy of Pediatrics 26.
After two doses, >99% of children achieve protective antibody levels (≥5 gpELISA units/mL), as stated by the American Academy of Pediatrics 26, 27.

ProQuad Age Recommendations

Age-Specific Dosing Guidelines

The Centers for Disease Control and Prevention recommends the first dose of ProQuad at 12-15 months and the second dose at 4-6 years of age 28
The second dose of ProQuad is routinely recommended at 4-6 years of age, before entering prekindergarten, kindergarten, or first grade 28
The second dose of ProQuad may be administered earlier than 4 years, provided at least 3 months have elapsed since the first dose 28

For the first dose in children aged 12-47 months, the CDC recommends using separate MMR and varicella vaccines rather than ProQuad unless parents express a preference for MMRV after discussing risks and benefits 28
ProQuad carries approximately one additional febrile seizure per 2,300-2,600 doses compared to separate vaccines in children aged 12-23 months 28
The CDC recommends ProQuad for children ≥48 months, as post-licensure studies demonstrated no increased febrile seizure risk in children aged 4-6 years receiving ProQuad compared to separate vaccines 28

Special Circumstances

A personal or family history of seizures is a precaution for ProQuad vaccination, and children with seizure history should receive separate MMR and varicella vaccines instead of ProQuad 28
For previously unvaccinated children of any age within the 12 months to 12 years range, ProQuad may be used to initiate the two-dose series, with the same age-based recommendations applying 28

Varicella Booster Vaccination for Immunocompetent Patients

Two-Dose Schedule: The Standard of Care

The Centers for Disease Control and Prevention recommends that all healthy individuals who have received one dose of varicella vaccine should receive a second dose to complete the two-dose series, with timing based on age: children aged 1-12 years should receive the second dose at 4-6 years, while adolescents and adults ≥13 years should receive it 4-8 weeks after the first dose 29
The two-dose varicella vaccination schedule is now the established standard for all immunocompetent individuals, replacing the previous one-dose recommendation, driven by compelling evidence of superior protection and the inability of single-dose vaccination to prevent outbreaks even in highly vaccinated populations 29, 30

Evidence Supporting Two Doses

Recipients of two doses are 3.3-fold less likely to develop breakthrough varicella compared to one-dose recipients 30
After two doses, >99% of children achieve protective antibody levels, compared to only 76-85% after a single dose 29, 30

Age-Specific Dosing Recommendations

The American Academy of Pediatrics recommends that children 12 months through 12 years receive the first dose of varicella vaccine at 12-15 months of age and the second dose at 4-6 years 29
The American Academy of Pediatrics recommends that adolescents and adults ≥13 years receive two 0.5 mL doses of single-antigen varicella vaccine, with a minimum interval of 4-8 weeks between doses 29

Contraindications for Immunocompetent Patients

The Centers for Disease Control and Prevention states that varicella vaccine should NOT be given to pregnant women, persons with history of anaphylactic reaction to neomycin or gelatin, and persons on high-dose systemic corticosteroids 31
The Centers for Disease Control and Prevention clarifies that egg allergy is NOT a contraindication, contact dermatitis to neomycin is NOT a contraindication, and having a pregnant household member is NOT a contraindication for vaccinating other family members 31

Varicella Vaccination Guidelines

Evidence of Immunity

A documented history of varicella disease verified by a healthcare provider constitutes evidence of immunity and is a valid reason to withhold varicella vaccination, as stated by the American Academy of Pediatrics, which explicitly includes "verification of a history of varicella disease or herpes zoster by a health care provider" as evidence of immunity 32
The American Academy of Pediatrics recommends that a verified history of varicella disease is sufficient to withhold varicella vaccination, as natural infection provides lifelong immunity that is superior to vaccine-induced immunity 33

Vaccination Recommendations

The American Academy of Pediatrics recommends against vaccinating individuals with documented immunity, as it provides no additional benefit and wastes resources 33
The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, indicates that immunoglobulin is only indicated for post-exposure prophylaxis in susceptible individuals within 96 hours of exposure, not for children who have already recovered from the disease 34, 35, 32

Clinical Considerations

The American Academy of Pediatrics advises against confusing this scenario with catch-up vaccination schedules for unvaccinated children, as a child with documented natural disease is fundamentally different from being unvaccinated but susceptible 33
The American Academy of Pediatrics recommends ensuring documentation of the verified varicella history is placed in the medical record to prevent future unnecessary vaccination attempts 32

Varicella Vaccination Guidelines

Evidence of Immunity

The Advisory Committee on Immunization Practices (ACIP) recognizes a diagnosis of varicella by a healthcare provider or a healthcare provider verification of a history of disease as evidence of immunity, which is a valid reason to withhold varicella vaccination 36
Written documentation of healthcare provider verification of varicella history should be considered valid evidence, as parental reporting alone is insufficient, particularly in young children where the positive predictive value is only 75% in unvaccinated children aged 12 months-4 years 36

Live‑attenuated Varicella Vaccine Contraindicated During Active Chickenpox

Immunological Rationale

Administering the live‑attenuated varicella vaccine to a child with confirmed active varicella infection provides no immunological benefit because natural infection already induces immunity, and the vaccine does not augment the immune response; therefore vaccination during active disease is contraindicated. [37][38]

Resource Utilization

Giving the varicella vaccine while the child is actively infected unnecessarily consumes healthcare resources without any clinical advantage. [37][38]

Varicella Vaccination and Immune Globulin Use in Children with Documented Prior Infection

Vaccination Schedule and Immunity Status

The CDC’s MMWR (2007) specifies that the routine varicella vaccination schedule for susceptible children includes a first dose at 12–15 months of age and a second dose at 4–6 years of age; however, children with health‑care‑provider‑verified prior varicella infection are considered immune and do not require these vaccinations. 39

Indications for Varicella‑Zoster Immune Globulin (VZIG/VariZIG)

The CDC’s MMWR (1999) states that VZIG/VariZIG is indicated only for post‑exposure prophylaxis in susceptible individuals who receive the product within 10 days of exposure to prevent or attenuate varicella disease. 40
Clinical Infectious Diseases (2014) confirms that VZIG is inappropriate for children who have recovered from natural varicella infection, because they are no longer susceptible and therefore do not benefit from immune‑globulin prophylaxis. 41

Varicella Vaccination Recommendations

Routine Immunization Schedule for Children (12 months – 12 years)

Healthy children should receive two doses of varicella vaccine: the first dose at 12‑15 months and the second dose at 4‑6 years of age, with a minimum interval of 3 months between doses for children aged 1‑12 years. 42
The first dose is administered at 12‑15 months of age. 43
The second dose is given at 4‑6 years of age, before entry into pre‑kindergarten, kindergarten, or first grade. 43
A minimum interval of 3 months must be observed between the two doses in children. 42

Catch‑Up Immunization for Children

Children who have missed the second dose should complete the two‑dose series by age 11‑12 years. 43

Vaccine Formulation Options for Children

The monovalent varicella vaccine (Varivax) is approved for all ages ≥ 12 months and is administered as 0.5 mL subcutaneously. 44
The combination MMRV vaccine (ProQuad) is approved only for ages 12 months through 12 years. 42

Routine Immunization Schedule for Adolescents and Adults (≥ 13 years)

Two doses of 0.5 mL subcutaneously are required. 42
A minimum interval of 4 weeks (28 days) between doses must be observed. 42
A recommended interval of 4‑8 weeks between doses is suggested to optimize immunity. 42
Only the single‑antigen varicella vaccine (Varivax) may be used; MMRV is not licensed for this age group. 42

Priority Groups for Adult Vaccination

Household contacts of immunocompromised persons should be vaccinated. 42
Non‑pregnant women of child‑bearing age should receive vaccination. 42
International travelers lacking evidence of immunity should be vaccinated. 45

Contraindications in Immunocompromised Patients

Highly immunocompromised individuals (e.g., severe HIV infection with CD4 < 15 % or CD4 < 200 cells/mm³, hematologic or solid tumors, long‑term immunosuppressive therapy) should not receive varicella vaccine. 45

Corticosteroid‑Related Precautions

High‑dose systemic corticosteroids (≥ 2 mg/kg/day prednisone or ≥ 20 mg/day) administered for ≥ 14 days are a contraindication to vaccination. 44
Vaccination should be deferred for at least 1 month after discontinuation of high‑dose systemic corticosteroids. 44
Inhaled, nasal, and topical steroids do not contraindicate vaccination. 44

Special Populations Eligible for Vaccination

HIV‑infected children who are asymptomatic with CD4 % ≥ 15 % (age 9 months‑5 years) or CD4 count ≥ 200 cells/mm³ (adults) may receive the vaccine using a 2‑dose schedule with a 3‑month interval; the single‑antigen varicella vaccine must be used. 45
Patients with primary complement deficiency or chronic granulomatous disease without T‑cell defects may receive a 2‑dose schedule separated by 3 months. 45

Pre‑Immunosuppression Vaccination Strategy

Ideally vaccinate ≥ 4 weeks before initiating immunosuppressive therapy. 45
Use a 2‑dose schedule: ≥ 28 days interval for individuals ≥ 13 years and ≥ 3 months interval for children 1‑12 years. 45
Protective immune response is achieved within 2‑3 weeks, and the attenuated virus is cleared by 3 weeks post‑vaccination. 45

Evidence of Immunity (No Vaccination Required)

Adults born in the United States before 1980 are considered immune and do not require vaccination (except healthcare personnel and pregnant women). 42

Absolute Contraindications

Pregnancy: vaccination is contraindicated; the first dose should be administered after pregnancy, with the second dose 4‑8 weeks later. 42
Severe anaphylactic reaction to vaccine components such as neomycin or gelatin. 44
Active, untreated tuberculosis. 44

Non‑Contraindications

Egg allergy is not a contraindication because the vaccine contains no egg protein. 44

Post‑Exposure Prophylaxis

Varicella‑zoster immune globulin (VariZIG) is indicated for susceptible high‑risk individuals (e.g., immunocompromised persons, pregnant women without immunity, certain neonates) when administered within 10 days of exposure. 45